Brian Silver is the Chief Financial Officer at TScan Therapeutics. Prior to joining TScan, Brian served as Freeline Therapeutics’ CFO and Head of Corporate Development, overseeing the Company’s financial, corporate legal and business development operations, including corporate strategy, BD&L, legal and compliance, investor relations, accounting, financial planning and analysis, IT, tax and treasury. In just over two years at Freeline, Brian raised over $300 million in capital, via a crossover financing as well as in one of the largest ever Nasdaq IPOs for a UK-based clinical-stage biotech company.
Before joining Freeline, Brian was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading independent global advisory firm. Prior to that, Brian was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell.
Brian has worked with a range of large and emerging pharmaceutical and biotechnology clients during his 25-year Wall Street career. His investment banking and corporate law advisory experience includes dozens of M&A and financing transactions across all capital markets, including IPOs, follow-ons, high yield and investment grade debt, and royalty financings. His M&A experience includes sell side and buy side transactions and leveraged buyouts, as well as reverse mergers and corporate restructurings.
Brian received a BA with honors from Harvard College and a JD with honors from the University of Chicago Law School.
What is Brian M. Silver's net worth?
The estimated net worth of Brian M. Silver is at least $131,096.07 as of December 27th, 2022. Mr. Silver owns 29,727 shares of TScan Therapeutics stock worth more than $131,096 as of November 17th. This net worth evaluation does not reflect any other investments that Mr. Silver may own. Learn More about Brian M. Silver's net worth.
How do I contact Brian M. Silver?
Has Brian M. Silver been buying or selling shares of TScan Therapeutics?
Brian M. Silver has not been actively trading shares of TScan Therapeutics within the last three months. Most recently, on Tuesday, December 27th, Brian M. Silver bought 2,842 shares of TScan Therapeutics stock. The stock was acquired at an average cost of $1.50 per share, with a total value of $4,263.00. Following the completion of the transaction, the chief financial officer now directly owns 29,727 shares of the company's stock, valued at $44,590.50. Learn More on Brian M. Silver's trading history.
Who are TScan Therapeutics' active insiders?
Are insiders buying or selling shares of TScan Therapeutics?
In the last year, TScan Therapeutics insiders bought shares 5 times. They purchased a total of 48,830 shares worth more than $248,928.70. In the last year, insiders at the sold shares 1 times. They sold a total of 164,686 shares worth more than $951,885.08. The most recent insider tranaction occured on September, 23rd when Director Barbara Klencke bought 5,000 shares worth more than $26,450.00. Insiders at TScan Therapeutics own 2.8% of the company.
Learn More about insider trades at TScan Therapeutics. Information on this page was last updated on 9/23/2024.
